US combi product dispute guidance from FDA
This article was originally published in Clinica
The US FDA has issued a guidance on filing dispute resolution requests when the agency fails to review and act on a combination product submission within the statutory time frame. In addition to noting who to contact and what to include in the request, the guidance explains when a formal request is appropriate and when it is not.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.